Document:

exv10w2

EXHIBIT 10.2

 

LICENSE AND DISTRIBUTION AGREEMENT

between

CHIESI FARMACEUTICI S.p.A.

and

CORNERSTONE THERAPEUTICS INC.

Dated May 6, 2009

 

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commission.

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	Page
	 
	 	 	 	 
	ARTICLE 1 DEFINITIONS
	 	 	2	 
	ARTICLE 2 GRANT
	 	 	6	 
	ARTICLE 3 OBLIGATIONS OF CORNERSTONE
	 	 	6	 
	ARTICLE 4 MARKETING AUTHORIZATION AND
PHARMACOVIGILANCE
	 	 	8	 
	ARTICLE 5 SUPPLY AND MANUFACTURING
	 	 	10	 
	ARTICLE 6 FINANCIAL PROVISIONS
	 	 	16	 
	ARTICLE 7 MARKETING OF THE PRODUCT
	 	 	18	 
	ARTICLE 8 INTELLECTUAL PROPERTY
	 	 	19	 
	ARTICLE 9 REPRESENTATIONS, WARRANTIES AND
COVENANTS
	 	 	22	 
	ARTICLE 10 INDEMNIFICATION
	 	 	25	 
	ARTICLE 11 CONFIDENTIALITY
	 	 	26	 
	ARTICLE 12 TERM AND TERMINATION
	 	 	27	 
	ARTICLE 13 GENERAL PROVISIONS
	 	 	29	 

-i-

 

LICENSE AND DISTRIBUTION AGREEMENT

     This LICENSE AND DISTRIBUTION AGREEMENT (this “Agreement”) is made as of this 6th day
of May, 2009 (the “Effective Date”) between Chiesi Farmaceutici S.p.A. a company
incorporated under the laws of Italy, with its principal place of business at Via Palermo 26/A,
43100 Parma, Italy (“Chiesi”) and Cornerstone Therapeutics Inc. a corporation incorporated
under the laws of Delaware, with its principal place of business at 1255 Crescent Green Drive,
Suite 250, Cary, North Carolina 27518, USA (“Cornerstone”, and together with Chiesi, the
“Parties”, each a “Party”).

WITNESSETH

     WHEREAS, Chiesi has developed the Product (hereinafter defined) and Chiesi owns or Controls
(hereinafter defined) the entire right, title and interest to the Know-How (hereinafter defined)
and the Trademark (hereinafter defined), all of them relevant to the Product, and the right to
their exploitation in the Territory (hereinafter defined);

     WHEREAS, Chiesi had entered into a License and Supply Agreement dated as of June 1, 1994, as
amended (the “Former Agreement”) with Dey, L.P., formerly known as Dey Laboratories, L.P., (“Dey”),
pursuant to which Chiesi granted Dey an exclusive license to use and sell the Product under the
Trademark in the Territory;

     WHEREAS, Chiesi and Dey have entered into an Amendment and Settlement Agreement dated as of
May 4, 2009 (the “Dey Settlement Agreement”), pursuant to which they have agreed, inter alia, to
terminate the Former Agreement as of the Transfer Date;

     WHEREAS, Cornerstone has experience in the distribution, marketing and selling of ethical
pharmaceutical specialties for respiratory diseases in the Territory;

     WHEREAS, Chiesi and Cornerstone have entered into a Stock Purchase Agreement of even date,
pursuant to which Chiesi has agreed to purchase an aggregate of 1,600,000 shares of Cornerstone’s
common stock, par value $0.001 per share (the “Stock Purchase Agreement”);

     WHEREAS, Chiesi and Cornerstone have also agreed to enter into this Agreement, pursuant to
which Cornerstone will obtain a license from Chiesi for the purpose of importing, storing,
handling, promoting, distributing, marketing, offering for sale and selling the Product under the
Trademark in the Territory; and

     WHEREAS, the Parties intend to enter into a separate Technical Agreement (hereinafter defined)
relating to the quality and technical aspects of the Product and a separate Pharmacovigilance
Agreement (hereinafter defined).

     NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, and
intending to be bound, and it being understood that the above recitals shall be deemed to be
incorporated into and form part of this Agreement, the Parties hereby agree as follows:

 

 

ARTICLE 1

DEFINITIONS

     1.1 “Act” means the US Federal Food, Drug and Cosmetic Act of 1938, the Public Health Service
Act of 1944 and the regulations promulgated under those Acts, as may be amended from time to time.

     1.2 “Affiliate” shall mean, with respect to any person, any other person that directly, or
indirectly through one or more intermediaries, controls, is controlled by or is under common
control with the person specified. For this purpose, the term “control” (including the terms
“controlling,” “controlled by” and “under common control with”) means possession, direct or
indirect, of the power to direct or cause the direction of the management and policies of a person,
whether through the ownership of voting securities, by contract or otherwise.

     1.3 “Agency” means any applicable supra-national, federal, national, regional, state,
provincial or local regulatory agencies, departments, bureaus, commissions, councils or other
government entities regulating or otherwise exercising authority with respect to the manufacture,
packaging, labeling, testing, release, storage, handling, sale, distribution or use of the Product,
including the FDA.

     1.4 “Applicable Laws” means the Act and other laws, rules and regulations, (including any
rules, regulations, guidelines or other requirements of any Agency) applicable to the manufacture,
packaging, labeling, testing, release, storage, handling, sale, distribution or use of
pharmaceutical products, as may be in effect from time to time in the Territory.

     1.5 “Business Day” shall mean any day other than a Saturday, Sunday or other day on which
commercial banks located in New York City, New York are required or permitted by law to be closed
for the conduct of regular banking business.

     1.6 “Calendar Month” shall mean a single month starting on the first day of each month and
ending on the last day of that same month. “Calendar Quarter” shall mean the 3 month period
beginning on January 1 and ending on March 31; the period beginning on April 1 and ending on June
30; the period beginning on July 1 and ending on September 30; or the period beginning on October 1
and ending on December 31.

     1.7 “Certificate of Analysis” shall mean, for each batch of Product produced, a document
prepared by Chiesi or its contract manufacturer setting forth the measured and observable
characteristics of Product for the batch, and confirming that such batch meets the Specifications.
Each Certificate of Analysis shall include: (a) a listing of tests performed by or on behalf of
Chiesi or its contract manufacturer, test date(s), and test results, and a certification of the
accuracy of each of the foregoing; and (b) a reference to or inclusion of the related Certificate
of Compliance.

     1.8 “Certificate of Compliance” means a document identified as such, signed by the senior
quality manager, or designee, and provided by Chiesi or its contract manufacturer to Cornerstone
that states, certifies, warrants and reflects that each batch of Product was produced and tested in
compliance with the Specifications, cGMPs, the master batch record and all other applicable
regulatory documents.

2

 

     1.9 “Claims” shall mean all charges, complaints, actions, suits, proceedings, hearings,
investigations, claims and demands.

     1.10 “Controlled” or “to Control”, in relation to any Intellectual Property Rights shall mean
such Intellectual Property Rights in the possession (whether by ownership, license or other right,
other than pursuant to this Agreement) by a Party or its Affiliates with the ability to grant to
the other Party access and/or a license (or sublicense) as provided herein under such right without
violating the terms of any agreement or other arrangement with any Third Party and without
requiring any further consent from such Third Party.

     1.11 “Field of Use” shall mean all indications approved under the approved Marketing
Authorization for the Product in the Territory as of the Transfer Date.

     1.12 “First Commercial Sale” shall mean, with respect to the Product, the first arm’s-length
commercial sale for value to a Third Party after the Transfer Date. Sales for investigator
initiated trials, named patient programs, test marketing, non-registrational studies or any similar
instance where the Product is supplied at cost or without charge shall not constitute a First
Commercial Sale. For clarity, First Commercial Sale shall not include the distribution of
demonstration or training units that are not able to be operated or intended to be used as a
Product.

     1.13 “Force Majeure” shall mean in relation to either Party any occurrence beyond the
reasonable control of that Party.

     1.14 “Improvement” shall mean any discovery, development, invention, enhancement or
modification, patentable or otherwise, relating to the Product, including any analytical
methodology, ingredients, preparation, presentation, means of delivery or administration, use or
packaging of the Product.

     1.15 “IND(s)” shall mean any investigational new drug application filed with Regulatory
Authorities in the Territory for approval to perform a clinical trial.

     1.16 “Intellectual Property Rights” shall mean patents, trademarks, Know-How, service marks,
logos, trade names, rights in designs, copyright, domain names, utility models and other
intellectual property rights, whether registered or unregistered, and including applications for
registration, and all rights or forms of protection having equivalent or similar effect in the
Territory.

     1.17 “Know-How” shall mean all information, procedures, instructions, techniques, data,
technical information, knowledge and experience (including toxicological, pharmaceutical, clinical,
non-clinical, medical data and health registration data), designs, processing, specifications and
technology to the extent necessary to distribute, sell, or offer for sale the Product in the
Territory, whether in written, electronic or other form, as owned or Controlled by Chiesi.

     1.18 “Losses” shall mean any and all damages (including all incidental, consequential,
statutory and treble damages), awards, deficiencies, settlement amounts, defaults, assessments,

3

 

fines, dues, penalties, costs, fees, liabilities, obligations, liens, losses, and expenses
(including court costs, interest and reasonable fees of attorneys, accountants and other experts).

     1.19 “Marketing Authorization” shall mean all necessary regulatory and governmental approvals
and registrations, including NDA approvals, that are required by an Agency to market, distribute,
promote and sell the Product in the Territory.

     1.20 “Marketing Authorization Application(s)” shall mean any or all applications to a
Regulatory Authority in the Territory in order to obtain Marketing Authorization.

     1.21 “NDA” shall mean (a) the single application or set of applications for approval and/or
pre-market approval to make and sell commercially in the United States a pharmaceutical product
filed with the FDA, including all information included in Drug Master Files (DMFs) related to such
application(s), and any related registrations with or notifications to the FDA, and (b) all
supplements and amendments that may be filed with respect to any of the foregoing.

     1.22 “Net Sales” shall mean gross sales amount of the Product in finished packaging invoiced
or otherwise fiscally charged by Cornerstone to unrelated Third Parties in the Territory less (i)
any trade, quantity or cash discounts in amounts customary in the trade allowed to customers, (ii)
all sales or excise taxes, duties and similar charges made or incurred by reference to the sale of
the Product by Cornerstone, (iii) chargeback payments, rebates, fees, GPO (group purchasing
organization) administrative fees, and other similar adjustments for the Product, including those
granted on price adjustments, billing errors, reimbursements or similar payments granted or given
to Third Party wholesalers or other Third Party distributors, buying groups, health insurance
carriers or other institutions, including those paid in connection with such sales to any
governmental entity, (iv) freight, insurance and other transportation charges to the extent
included in the invoice price, and (v) customary allowances or credits, not exceeding the original
billing or invoice amount, granted by Cornerstone on account of claims, rejected or returned
Product.

     1.23 “Net Sales Price” shall mean the Net Sales during the previous Calendar Month/Quarter in
the Territory divided by the total number of units of Product to which such Net Sales were
attributable and calculated separately for each vial size of the Product.

     1.24 “Product” shall mean the finished, fully packaged, product containing a porcine lung
surfactant in vials of 1.5 and 3.0 ml manufactured under the Know-How and currently sold under the
Trademark pursuant to NDA # 020744.

     1.25 “Regulatory Authorities” shall mean any Agency which has responsibility in the Territory
for granting Marketing Authorization.

     1.26 “Regulatory Requirements” shall mean all applicable standards relating to drug products,
as identified in the Act.

     1.27 “SKU” shall mean a specific packaged presentation of a defined quantity of a specific
dosage strength of the Product, such as a vial of 1.5 or 3.0 ml identified by Chiesi by its Stock
Keeping Unit number, to be identified in the Territory by National Drug Code numbers identifying
Cornerstone as the labeler.

4

 

     1.28 “Specifications” shall mean all finished product specifications and packaging
specifications, pursuant to the Regulatory Requirements and as approved in the Territory under the
Marketing Authorization with which compliance is required for the fabrication, packaging, labeling,
testing, storage, handling, sale and release of the Product in the Territory, together with any
other specification indicated in the Technical Agreement separately signed by the Parties.

     1.29 “Territory” shall mean the United States of America and its territories and possessions.

     1.30 “Third Party” shall mean any entity other than Chiesi, Cornerstone and their respective
Affiliates.

     1.31 “Trademark” shall mean the Curosurf® trademark, USPTO registration number 1905266, and as
set out in Appendix A.

     1.32 Interpretation. Unless the context of this Agreement otherwise requires, (a) words of
one gender include the other gender; (b) words using the singular or plural number also include the
plural or singular number, respectively; (c) the terms “hereof,” “herein,” “hereby,” and derivative
or similar words refer to this entire Agreement; (d) the terms “Article” and “Section” refer to the
specified Article and Section of this Agreement; (e) all currencies shall be shown in United States
Dollars; and (f) whenever the words “include”, “includes” or “including” are used in this
Agreement, they shall be deemed to be followed by the words “without limitation”, whether or not
they are in fact followed by those words or words of like import. Whenever this Agreement refers
to a number of days, unless otherwise specified, such number shall refer to calendar days. The
English language shall be controlling in all respects in this Agreement.

     1.33 Additional Definitions. Each of the following definitions is set forth in the Section of
this Agreement indicated below:

	 	 	 	 	 
	Definition	 	Section
	Agreement
	 	Preamble
	cGMPs
	 	 	5.9.1	 
	Chiesi
	 	Preamble
	Chiesi Intellectual Property
	 	 	8.1	 
	Confidential Information
	 	 	11.1	 
	Cornerstone
	 	Preamble
	Dey
	 	Recitals
	Dey Settlement Agreement
	 	Recitals
	Effective Date
	 	Preamble
	Floor Price
	 	 	6.2	 
	Former Agreement
	 	Recitals
	Loss
	 	 	10.1	 
	Monthly Report
	 	 	6.4	 
	Parties
	 	Preamble
	Pharmacovigilance Agreement
	 	 	4.6	 
	Purchase Order
	 	 	5.3.2	 

5

 

	 	 	 	 	 
	Definition	 	Section
	Report
	 	 	6.4	 
	Rolling Forecast
	 	 	5.3.1	 
	Supply Price
	 	 	6.1	 
	Stock Purchase Agreement
	 	Recitals
	Technical Agreement
	 	 	5.2	 
	Term
	 	 	12.1	 
	Transfer Date
	 	 	4.1	 
	VAT
	 	 	6.3	 

ARTICLE 2

GRANT

     2.1 License Grant. Beginning on the Transfer Date, Chiesi hereby grants to Cornerstone, and
Cornerstone hereby accepts from Chiesi, a non-transferable, exclusive license under the Know-How
and the Trademark, for the purposes of importing, storing, handling, promoting, distributing,
marketing, offering for sale and selling the Product in the Territory for use in the Field of Use.

     2.2 External Opportunities. Cornerstone hereby agrees that, during the term of this
Agreement, and unless expressly agreed upon by the Parties in writing, Cornerstone shall not,
directly or indirectly, import, store, handle, promote, distribute, market, offer for sale or sell
the Product outside the Field of Use or outside the Territory. Furthermore, all inquiries or
orders received or known to Cornerstone relating to the (i) sale or delivery of the Product outside
the Territory or (ii) use of the Product outside the Field of Use shall be referred by Cornerstone
to Chiesi. It is Cornerstone’s responsibility to document and communicate the specific details of
all business opportunities relating to the foregoing to Chiesi.

     2.3 Sublicensing; Co-Promotion. Cornerstone shall not have the right to grant sublicenses
without the prior written consent of Chiesi. In addition, Cornerstone may not enter into any
co-promotion agreements concerning the Product for use in the Field of Use for sale in the
Territory without the express written consent of Chiesi as to the co-promoting Party, such approval
not to be unreasonably held or delayed. Cornerstone shall in any case be responsible to Chiesi for
all acts and omissions of such co-promoting Party, if any, as they relate to this Agreement.

ARTICLE 3

OBLIGATIONS OF CORNERSTONE

     The following obligations of Cornerstone shall begin upon the Transfer Date:

     3.1 Own Account. Cornerstone shall place orders for the Product with Chiesi and shall resell
the ordered Product to Cornerstone’s customers solely in the Field of Use in the Territory. In an
effort to ensure supply to the market within the Territory goes uninterrupted, Chiesi will use
commercially reasonable efforts to ensure adequate supply of Product is available for commercial
sales by Cornerstone based off the initial Rolling Forecast promptly upon Transfer.

6

 

     3.2 Efforts. Cornerstone shall promote, distribute, market, offer for sale and sale the
Product using commercially reasonable efforts to achieve maximum market impact and concentration
throughout the Territory, such efforts to be at least at the same level of effort, but not the same
number of full-time employees, as with other similar products of similar sales potential which
Cornerstone promotes, distributes, markets or sells. In addition, Cornerstone shall use
commercially reasonable efforts to ensure that the First Commercial Sale in the Territory occurs
promptly after Chiesi makes available commercial supplies of the Product after the Transfer Date.

     3.3 Information and Reports. Cornerstone shall provide Chiesi with written and oral reports,
market information, competitive activities, sales forecasts, development of prices and other
pertinent customer and industry information as may be reasonably required from time to time by
Chiesi and to keep Chiesi informed of Cornerstone’s activities and anticipated future orders. In
addition, Cornerstone shall keep Chiesi regularly informed of all other material details concerning
the promotion, distribution, marketing and sale of the Product in the Territory as Chiesi may
reasonably request.

     3.4 Facilities. Cornerstone, or its designees, shall maintain facilities in the Territory
suitable for the conduct of Cornerstone’s business, and in compliance with the Regulatory
Requirements. Cornerstone agrees that Chiesi may inspect, or have inspected, the facilities of
Cornerstone to determine compliance with the Regulatory Requirements associated with the storage
and distribution of the Product. In addition, Chiesi shall have the right, upon reasonable notice
and during business hours, to inspect or cause to be inspected at its own expense the facilities of
Cornerstone where the Product is stored.

     3.5 Records. Cornerstone and its designees, shall maintain accurate records pertaining to the
sale and distribution of the Product to its customers, for a period of at least one year after the
expiration date of each lot or batch of such Product, with sufficient detail to enable the recall
of such Product from the market. Cornerstone shall also maintain accurate records of all
complaints it has received regarding the Product, and the results of the investigation thereof, for
a period of at least one year after the expiration date of the lot or batch of such Product.

     3.6 Training. Cornerstone shall ensure that the Product is stored at a designated Third Party
logistics facility that is compliant with the Regulatory Requirements, and is shipped to its
customers, under the supervision of personnel having training sufficient to protect the health of
the consumer and purchaser. Cornerstone shall train and maintain an adequate staff of appropriate
personnel, sufficiently knowledgeable about the Product following Chiesi training guidelines, in
order to enable such personnel to effectively (i) promote the sale of the Product, (ii) respond to
customer inquiries and complaints and (iii) respond to inquiries from regulatory personnel.

     3.7 Compliance with Laws and Instructions. Cornerstone shall hold all applicable licenses,
and shall comply with all related directives, laws, rules and regulations, in connection with the
importation, storage, handling, promotion, distribution, marketing and sale of the Product in the
Territory. In its promotion, marketing or sale of the Product, Cornerstone agrees to avoid making
any statements, representations, warranties or guarantees concerning the Product except as
expressly authorized pursuant to the Marketing Authorization for the Product.

7

 

Cornerstone shall, in its importation, storage, handling, distribution, marketing and sale of
the Product, comply with the quality standards of Chiesi and at all times adhere to a level of
quality at least as high as Cornerstone maintains for similar activities conducted in relation to
its other products.

     3.8 Inventory. Cornerstone shall maintain sufficient stocks of Product to meet all reasonably
foreseeable demands for the Product in the Territory without undue delay, and in no event to
maintain less stock than [***]. Cornerstone shall not be held to the aforementioned standard in
the event of inventory shortfall arising from supply issues from Chiesi.

     3.9 Selling Costs. For the avoidance of doubt, all importing, storing, handling, promoting,
distributing, marketing and selling costs and expenses relating to the Product within the Territory
shall be borne exclusively by Cornerstone.

     3.10 Employees. Cornerstone hereby commits to make offers of employment, effective upon the
Transfer Date, to the Employees (as defined below). Cornerstone shall be entitled to have
reasonable contact with the Employees to discuss their potential employment with Cornerstone, but
shall not contact the Employees directly. Cornerstone shall make requests for contact with
Employees through Dey’s designated Alliance Manager. If Cornerstone chooses [***].
Notwithstanding the foregoing and subject to relevant law, if Cornerstone is unable[***]. For the
purposes of this Section 9.2.4, “Employee” shall mean up to [***] and up to [***] employed by Dey
prior to the Transfer Date and dedicated to the Product. Such employment by Cornerstone of the
Employees shall be subject to the provisions of Section 12.5.

ARTICLE 4

MARKETING AUTHORIZATION AND PHARMACOVIGILANCE

     4.1 Transfer of Marketing Authorization. Chiesi shall procure the transfer of the Marketing
Authorization currently held by Dey in the Territory to Cornerstone using Cornerstone Regulatory
Counsel as of [***] (the “Transfer Date”). All expenses related to Marketing
Authorization transfer procedures shall be borne by Cornerstone.

     4.2 Maintenance. Upon the Transfer Date, Cornerstone shall be fully responsible for, at its
own expense, taking such steps and actions, in accordance with instructions provided by Chiesi from
time to time, as may be necessary and advisable to maintain the Marketing Authorization held by
Cornerstone in the Territory, including making all applications, requests for authorizations and
submissions of information related to the Marketing Authorization Application. Should the Parties
mutually desire a new Marketing Authorization Application, pre-clinical and clinical testing
connected with or related to relevant IND(s) and Marketing Authorization Application(s) shall be at
an equally shared cost between Cornerstone and Chiesi. However, to the extent that Cornerstone
unilaterally desires a new Marketing Authorization Application, then Cornerstone shall be solely
responsible for all costs and expenses associated with pre-clinical and clinical testing connected
with or related to relevant IND(s) and Marketing Authorization Application(s).

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.

8

 

     4.3 Protocols. Prior to the commencement of any external scientific investigation,
Cornerstone shall provide Chiesi, for Chiesi’s approval, with a protocol, including the relevant
clinical report form, for any study to be undertaken by Cornerstone with the Product. Chiesi shall
have the right to disagree with or request a modification of such proposed study, should it be
reasonably deemed harmful for the sound international development of the Product. Chiesi shall
reply in writing no later than twenty (20) Business Days from the receipt of the protocols in
question, otherwise the protocols will be deemed accepted by Chiesi.

     4.4 Reports/Studies.

          4.4.1 Study Reports. Cornerstone undertakes to keep Chiesi duly and fully informed of
the efforts made by Cornerstone pursuant to Section 4.3, by providing Chiesi upon request, but no
less frequent than every six (6) months, with detailed reports in writing informing Chiesi of the
progress made and results of the studies performed with the Product in the Territory.

          4.4.2 Cornerstone Study Results. Cornerstone shall make available to Chiesi, as soon
as possible, results of all studies made with the Product to the extent Cornerstone has Control of
such results. Chiesi shall be free to use, directly or indirectly, all such results in and outside
the Territory free of charge.

          4.4.3 Chiesi Study Results. Chiesi shall make available to Cornerstone, as soon as
possible, results of all studies made with the Product to the extent Chiesi has Control of such
results. Cornerstone shall be free to use, directly or indirectly, all such results in the
Territory pursuant and subject to the terms of this Agreement.

          4.4.4 Regulatory Status. Furthermore, Cornerstone shall keep Chiesi informed of the
status of IND(s), Marketing Authorization Application(s), Marketing Authorization and other
authorizations held or managed by Cornerstone pursuant to Section 4.2, by providing Chiesi with
documents and reports in the following manner:

               (a) with respect to IND(s) or Marketing Authorization Application(s) or Marketing
Authorization, Cornerstone shall regularly, and in any case within twenty (20) Business Days,
inform Chiesi of any submissions or grants thereof by sending Chiesi a written report by the most
appropriate means of transmission; and

               (b) with respect to any and all filings, authorizations, acceptances, permissions, material
correspondence or similar relevant documents, Cornerstone shall provide Chiesi with copies, by the
most appropriate means of transmission, regularly upon dispatch or receipt thereof and in any case
within forty (40) Business Days.

     4.5 Meetings. The Parties shall meet at least twice a year in person, unless otherwise
mutually agreed by the Parties, to share, discuss and evaluate medical, scientific, legal, quality
and regulatory information relevant to the Product.

     4.6 Pharmacovigilance. The Parties agree that, upon execution of this Agreement, and in no
event later than ten (10) weeks after the Effective Date, they shall enter into a separate
pharmacovigilance agreement, containing all customary terms and conditions, for the exchange

9

 

of adverse event and safety information, including pregnancy exposure data concerning the
Product (the “Pharmacovigilance Agreement”). Until the Pharmacovigilance Agreement is
finalized, the Parties shall exchange such data in a manner that enables each Party to fulfill
regulatory requirements within their own territories (and within any other limits of this
Agreement).

ARTICLE 5

SUPPLY AND MANUFACTURING

     5.1 Responsibility for Manufacturing. Except as otherwise provided in this Agreement, Chiesi
shall use commercially reasonable efforts to produce and supply to Cornerstone its entire
requirements of the Product for use in the Field of Use for sale in the Territory in response to
Purchase Orders (as defined below). Cornerstone will purchase exclusively from Chiesi the Product
for use in the Field of Use for sale in the Territory. During the Term, Chiesi, and its contract
manufacturer, collectively shall hold and maintain all licenses and permits, for the Term of this
Agreement, as are required to fabricate, package, label, test and store the Products in the
Territory, and sell the Products to Cornerstone.

     5.2 Technical Agreement. Upon execution of this Agreement, the Parties shall promptly, and in
no event later than ten (10) weeks after the Effective Date, enter into a separate technical
agreement, whereby the Parties will define their respective responsibilities in relation to the
cGMPs and quality matters, technical specifications, release and the supply of the Product (the
“Technical Agreement”). The Technical Agreement shall include examples of the Certificate
of Analysis and Certificate of Compliance.

     5.3 Forecasting and Ordering.

          5.3.1 Rolling Forecasts. Cornerstone shall submit to Chiesi by the first day of each Calendar
Month during the Term, a forecast of Products that Cornerstone anticipates ordering from Chiesi,
including samples, for each of the following [***] (“Rolling Forecast”). The first [***]
months of each Rolling Forecast shall be considered as binding, the quantities indicated for the
months from the [***] up to the [***] month can be varied by Cornerstone by no more than +/- [***]
percent ([***]%) compared to the previous Rolling Forecast, while the quantities indicated for the
months from the [***] up to the [***] month can be varied by Cornerstone by no more than +/- [***]
percent ([***]%) compared to the previous Rolling Forecast, while the quantities indicated for the
months after the [***] month can be freely varied by Cornerstone compared to the previous Rolling
Forecast. Cornerstone acknowledges that Products are produced in full lot quantities, as set forth
on Appendix B, and all Purchase Orders shall be in full batch quantities.

          5.3.2 Purchase Orders; Documentation. Cornerstone agrees to place purchase orders for the
Product with Chiesi according to the above binding portion of the Rolling Forecast at least [***]
prior to the start of each Calendar Month for quantities of the Product to be delivered hereunder
(each, a “Purchase Order”). Each Purchase Order shall be placed by Cornerstone with Chiesi
by e-mail and shall set forth, for each Product, the quantity ordered (in full batch quantities)
and delivery date. Chiesi agrees to confirm such Purchase Orders within

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.

10

 

[***] Business Days of receipt, in whole or in part, such confirmation not to be unreasonably
withheld. To the extent that any Purchase Order is so confirmed by Chiesi, then such Purchase
Order shall be filled and delivered in accordance with its terms and the terms of this Agreement.
The Parties agree to discuss in good faith any Purchase Orders not so confirmed by Chiesi. If
Chiesi notifies Cornerstone that it is unable to fill a Purchase Order that has previously been so
confirmed, Chiesi shall indicate the portion of such Purchase Order that it cannot supply by the
requested delivery date and specify alternate delivery dates.

          5.3.3 Accommodations. From time to time, due to significant unforeseen circumstances,
Cornerstone may deliver to Chiesi a Purchase Order for Product volumes in excess of those specified
in the above binding portion of the Rolling Forecast. The Parties agree to discuss in good faith
any Purchase Orders delivered by Cornerstone requesting Product volumes in excess of the Product
volume specified in the above binding portion of the Rolling Forecast. In determining whether to
fill such excess Product Purchase Orders requested by Cornerstone, Chiesi shall have the right to
take into consideration (i) its current on-hand supply of Product, (ii) its own Product needs,
(iii) the needs of third parties with whom Chiesi has Product supply obligations, (iv) its existing
capacity and (iv) any other factor reasonably relevant to the feasibility of fulfilling such excess
supply request.

          5.3.4 [***].

     5.4 Terms of Orders. The terms of this Agreement are hereby incorporated by reference into
each order of Product submitted by Cornerstone and accepted by Chiesi. In the event of any
conflict between a Rolling Forecast or Purchase Order or other written instructions and this
Agreement, the terms of this Agreement shall prevail.

     5.5 Packaging. Cornerstone shall be entitled to define its requirements regarding the inner
and outer packaging of the Product as long as technically feasible as further detailed in the
Technical Agreement, it being understood that major outer packaging requirements shall require
prior approval by Chiesi. In addition, should Cornerstone wish to change the artwork of the
packaging during the Term, then Chiesi shall implement such changes as long as technically
feasible, and Cornerstone shall reimburse Chiesi for the related expenses, including expenses for
already ordered and paid relevant materials prior to the above changes that cannot be used for
other purposes. Should Chiesi request changes to the artwork, for technical reasons or otherwise,
then Chiesi shall implement such changes and shall fully bear the related expenses. Furthermore,
in the event that any Regulatory Authorities impose changes to the artwork, then the Parties shall
equally share the related expenses; provided, however, that Cornerstone shall reimburse Chiesi for
the expenses related to materials already ordered and paid prior to the above changes and such
materials cannot be used for other purposes providing that the imposed changes by any Regulatory
Authority were not as a direct result of an issue involving Chiesi or their contract manufacturers.

     5.6 Inspection of Facilities. At its discretion, Chiesi shall inspect, or have inspected, the
facilities of any of Chiesi’s contract manufacturers of the Products to determine compliance of
such contract manufacturer with the Regulatory Requirements associated with the fabrication

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.

11

 

packaging, labeling, testing and storage of the Product. Chiesi will pay all fees associated with
such inspection, including inspections under Regulatory Requirements. Subject to the terms of the
Technical Agreement, Chiesi shall share the results of any such audit with Cornerstone. In
addition, Cornerstone shall have the right, upon reasonable notice, once a year and during business
hours, to inspect or cause to be inspected at its own expense the facilities of Chiesi where the
Product is manufactured; provided, however, Chiesi shall permit Cornerstone or Cornerstone
representatives to conduct additional on-site “for cause” technical and/or cGMP reviews and/or
audits if the issues leading to the need to conduct the “for cause” review and/or audit cannot be
resolved without such an on-site meeting.

     5.7 Records. Chiesi shall, or shall require its contract manufacturer to, maintain accurate
books and records pertaining to the manufacture and release of the Products, as required by the
Regulatory Requirements, including all of the manufacturing and analytical records, all records of
shipments of Products, and all data relating to Products and complaints Chiesi has received
therefor, for the time periods required by the Regulatory Requirements. Chiesi agrees that, in
response to any complaint, or in the defense by Cornerstone of any litigation, hearing, regulatory
proceeding or investigation relating to Products, Chiesi shall make available to Cornerstone such
Chiesi employees and records reasonably necessary to permit the effective response to, defense of,
or investigation of such matters, subject to appropriate confidentiality protections.

     5.8 Notification. Chiesi shall provide Cornerstone with written notice as soon as practicable
of all claims and allegations, of which Chiesi becomes aware, that Chiesi, or its contract
manufacturer, is not complying with the Regulatory Requirements associated with the manufacture or
release of Products in the Territory, or that the Products do not comply with the Specifications
therefor, which claims or allegations Chiesi reasonably believes to warrant investigation or
response.

     5.9 Supply by Chiesi.

          5.9.1 Supply of Product. Chiesi shall deliver Product to Cornerstone in such
quantities and at such times as ordered by Cornerstone pursuant to Section 5.3.2. The Products
supplied by Chiesi to Cornerstone shall be (a) in finished pharmaceutical form, (b) conform to
relevant Specifications and all Applicable Laws and regulations, and (c) be packaged in a version
suitable for the market (e.g., English language packaging and labeled in a manner as required
pursuant to the Marketing Authorization). All such Products shall be fabricated, packaged,
labeled, tested and stored in compliance with Chiesi’s quality policy, which is implemented by the
relevant quality management system, such system being fully in compliance with the applicable
regulatory requirements, including current Good Manufacturing Practices (“cGMPs”) and in
accordance with the Regulatory Requirements and the Specifications as per the terms of the
Technical Agreement.

          5.9.2 Packaging. Chiesi shall be responsible for the packaging of the Product into
final market packaging. The NDC number for each SKU shall include the Cornerstone labeler code and
the Cornerstone corporate logo will be included on the packaging. Cornerstone acknowledges that
Chiesi is the owner of all rights, title and interest to the copyrights in all

12

 

packages, labeling and inserts related to the Product. Cornerstone’s use of the materials
owned by Chiesi shall inure to the benefit of Chiesi for all purposes.

          5.9.3 Delivery Dates. Chiesi shall use commercially reasonable efforts to meet the
delivery dates and order quantities indicated in Cornerstone’s Purchase Orders. Any shipment
delivered that is within plus or minus [***] percent (+/-[***]%) of the quantity ordered and/or
plus or minus [***] (+/- [***]) Business Days of the delivery date specified on the relevant
Purchase Order will be considered as delivered on time.

          5.9.4 Shelf Life. Subject to Applicable Laws, the remaining shelf life of the Product
supplied by Chiesi to Cornerstone shall be at least equal to [***] months at the time of receipt by
Cornerstone or any of its designees; provided, however, that, to the extent Chiesi has Product
available with a remaining Shelf Life of longer than [***] months, Chiesi shall exercise reasonable
efforts to supply Cornerstone with such Product. In the event that, for any reason, the remaining
shelf life of Product supplied is less than [***] months at the time of receipt by Cornerstone or
any of its designees, then Cornerstone may elect, at its discretion, to accept such Product
notwithstanding such fact. Cornerstone shall discuss such situation with Chiesi prior to accepting
or refusing shipment. Notwithstanding the foregoing, the stocks of the Product repurchased by
Chiesi from Dey [***] pursuant to the Dey Settlement Agreement [***]. In addition, to the extent
that Dey [***].

          5.9.5 Manufacturing Changes. Required and discretionary manufacturing changes and
handling thereof are to be addressed in the Technical Agreement.

     5.10 Shipment; Title; Transport.

          5.10.1 Shipment; Single Order. All Product (including Product for export) shall be
delivered [***] in accordance with Cornerstone’s instructions. Any shipment of the Product shall
be accompanied by the relevant Certificate of Analysis as well as additional documentation as
further specified in the Technical Agreement or as needed by customs and other Regulatory
Authorities in the Territory relating to import and export. To the extent possible, Product which
is purchased in a single order shall be delivered by Chiesi in a single shipment unless Cornerstone
directs that such Product should be delivered to more than one location.

          5.10.2 Title; Risk of Loss. Title, possession and risk of loss shall pass to
Cornerstone upon delivery of Product to Cornerstone’s designated carrier; provided, however, that
nothing in this Section shall in any manner limit Cornerstone’s rights under Section 5.11. If any
Product is rejected by Cornerstone after shipment under this Agreement, and such Product is to be
returned to Chiesi, then title to and risk of loss with respect to such rejected Products shall
pass from Cornerstone to Chiesi when such Products are placed in the possession of the carrier for
return to Chiesi or for shipment on behalf of Chiesi to a destination designated by Chiesi.

     5.11 Acceptance of Delivery. All Claims for failure of any delivery of Product to conform to
the Specifications or for a short delivery, must be made by Cornerstone in writing

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.

13

 

within [***] following receipt of delivery of such Product, or in the case of latent or inherent
defects not detectable by inspection upon receipt of the Product, within [***] as of the date of
discovery. Cornerstone shall provide Chiesi with details of the allegedly defective Product,
including samples thereof, and shall cooperate in any investigation Chiesi should wish to carry
out. Chiesi shall use its reasonable endeavors to replace as soon as possible the non-conforming
Product or to make up for any short delivery of Product, it being understood that only if the
non-conformity or short delivery is due to causes under the control or responsibility of Chiesi,
the replacement of the defective Product or replenishment for the short delivery shall be free of
charge to Cornerstone. Without limiting the foregoing, Cornerstone or its designee receiving
non-conforming Product shall, at Chiesi’s option, either (i) return the affected Product to Chiesi
for rework or reprocessing by Chiesi, all at Chiesi’s expense; (ii) return the affected Product for
destruction by Chiesi at Chiesi’s expense; or (iii) have the Product disposed of by a Third Party
designated by Cornerstone at Chiesi’s expense and in accordance with Applicable Laws.

     5.12 Limitation. For the avoidance of doubt and without prejudice to the provisions of
Article 10, Chiesi’s responsibility is limited to the shipment of goods for the above-mentioned
replacement or replenishment only, it being however understood that in case Cornerstone fails to
notify Chiesi within the above deadlines, Cornerstone’s rights under this Section shall be
forfeited; provided, however, a recall of the Product shall be governed by Section 5.16 of this
Agreement. Failure to make timely claims in the manner prescribed shall constitute acceptance of
the delivery and no further claims after such [***] period may be made by Cornerstone against
Chiesi and no returns shall be accepted by Chiesi after such date.

     5.13 Independent Testing. If a dispute arises between Cornerstone and Chiesi concerning the
defective quality or short delivery as set out in Section 5.11 above, and reasons thereof, of the
Product, and said dispute is not resolved within twenty (20) Business Days from the receipt by
Chiesi of the notification mentioned in Section 5.11 above, the Parties shall within thirty (30)
days appoint an independent first class laboratory to undertake the relevant testing and its
findings shall be conclusive and binding upon the Parties. All costs relating to this process
shall be borne solely by the unsuccessful Party.

     5.14 Meetings. The Parties will, at least once per Calendar Quarter, discuss in a meeting or
via telephone any supply chain or other delivery issues that have arisen during the preceding
Calendar Quarter.

     5.15 Training. Chiesi shall provide technical training and support and Product information,
where and at such times as Chiesi deems appropriate or if reasonably requested by Cornerstone, to
Cornerstone and customers for the mutual benefit of Chiesi and Cornerstone.

     5.16 Recalls. In the event (i) any Agency issues a directive, order or, following the
issuance of a safety warning or alert with respect to a product, a written request that any Product
be recalled, (ii) a court of competent jurisdiction orders such a recall, or (iii) Cornerstone
determines that any Product should be recalled or that a “dear doctor” letter is required relating

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.

14

 

to the restrictions on the use of the Product, Chiesi will co-operate with those activities
relating to the Product as reasonably required by Cornerstone, having regard to all Applicable
Laws. In the event of a recall of the Product, Cornerstone will notify Chiesi in accordance with
the Pharmacovigilance Agreement, and Chiesi will cooperate with those recall activities relating to
the Product as reasonably required by Cornerstone.

          5.16.1 Cornerstone or its designated agent shall have the responsibility for handling customer
returns of the Product. Chiesi shall provide Cornerstone or its designated agent with such
assistance as Cornerstone may reasonably require to handle such Product returns.

          5.16.2 To the extent that a recall or return results from, or arises out of, a failure by
Chiesi (or its contract manufacturer) to manufacture and supply the Product in accordance with the
Specifications, Applicable Laws and/or cGMP, at Cornerstone’s option, Chiesi shall be responsible
for the documented out-of-pocket expenses of such recall or return and shall either (i) reimburse
Cornerstone for the price that Cornerstone paid to Chiesi for manufacturing the Product which are
the subject of the recall, including the actual costs incurred in shipping, applicable transit
charges, insurance premiums, duties, taxes paid or any other out-of-pocket charges incurred in
connection with delivery of such Product to Cornerstone or its designee, or (ii) use its
commercially reasonable efforts to replace the recalled or returned Product with new Products at no
charge to Cornerstone. Additionally, Chiesi shall reimburse or credit Cornerstone for any
out-of-pocket costs paid by Cornerstone to Third Parties for transportation and destruction of the
affected Product, and pay or provide a credit to Cornerstone for the actual administrative expenses
and all other reasonable costs incurred by Cornerstone outside of the ordinary course of business
in connection with the disposition of a Product under this Section 5.16.2. For the purpose of
clarity, Cornerstone shall be fully and solely responsible for all costs and expenses related to
any recall initiated for any other reason. The Parties shall use commercially reasonable efforts
to comply with their obligations under this Section 5.16.2 in a timely manner.

          5.16.3 Cornerstone or its designated agent shall have the full responsibility for responding
to questions and complaints from Cornerstone’s customers for the Product. Responsibilities and
activities relating to complaints and questions are defined in the Pharmacovigilance Agreement.
Unless it is determined that the cause of any customer complaint resulted from a failure by Chiesi
to provide manufacturing services in accordance with the Specifications, Applicable Laws or cGMP,
all costs incurred in respect of this Section 5.16.3 shall be borne by Cornerstone.

ARTICLE 6

FINANCIAL PROVISIONS

     6.1 Supply Price. The purchase price (“Supply Price”) for Product purchased from
Chiesi shall be an amount equal to [***] percent ([***]%) of the Net Sales Price for such Product;
provided that in no such event shall the Supply Price be less than the Floor Price calculated in
accordance with Section 6.2.

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.

15

 

     6.2 Floor Price. The initial floor price for the Product shall be as set forth on
Appendix B (the “Floor Price”) and shall remain firm and valid until [***].
Thereafter, Chiesi may adjust the Floor Price [***] in accordance with the evolution of
manufacturing and other relevant costs.

     6.3 Payment Terms. All payments due to Chiesi under this Agreement shall be made by
Cornerstone by wire transfer in USD, within [***] calendar days from the invoice date, to a bank
account as may be designated by Chiesi from time to time; provided that the payments due under this
Agreement are exclusive of Value Added Tax (“VAT”) and Cornerstone shall pay to Chiesi any
VAT which is or may become properly payable or chargeable in respect of the payments, according to
the payment terms set forth hereunder; provided, that Chiesi shall use commercially reasonable
efforts to procure any available exemption from or refund of applicable VAT (and, in the event
Chiesi or any of its Affiliates obtains such a refund, it shall promptly remit such refund to
Cornerstone).

     6.4 Reports. Within [***] after the end of each Calendar Quarter after the Transfer Date,
Cornerstone shall deliver a report to Chiesi (a “Report”) specifying, for such Calendar
Quarter in the Territory:

          6.4.1 the quantities of each SKU of Product sold by Cornerstone in that Calendar Quarter;

          6.4.2 gross sales and the calculation of Net Sales of Product by SKU in the Territory during
such Calendar Quarter;

          6.4.3 all quantities of Product distributed free of charge, together with any documents
evidencing such use;

          6.4.4 the Net Selling Price for each SKU of Product sold in that Calendar Quarter in the
Territory; and

          6.4.5 the total amount payable to Chiesi for all SKUs of the Product delivered during such
Calendar Quarter calculated in accordance with Section 6.1 using the Net Sales Price for each SKU
in the Territory for the just-ended Calendar Quarter.

     6.5 Records.

          6.5.1 Audit. Cornerstone shall keep and maintain true and complete records setting
forth the gross sales of the Product in the Territory, and of all matters relating to the
computation of the Net Sales of the Product in the Territory, including quantities of Product used
as clinical supplies or in patient assistance programs, volume of Product distributed, or records
otherwise related to Cornerstone’s performance of its obligations under this Agreement, for a
period of [***] following such sales, such records shall be open to inspection at Cornerstone’s
corporate headquarters on thirty (30) days written notice provided by Chiesi, during the normal

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.

16

 

office hours of Cornerstone (but not more frequently than once per year) by a nationally recognized
independent certified public accountant selected by Chiesi and reasonably acceptable to
Cornerstone, and retained solely for the purpose of auditing the same at Chiesi’s expense;
provided, however, that records with respect to any Calendar Quarter may be audited no more than
once in connection with the same audit and/or subject matter; provided, further that nothing in
this Section 6.5.1 shall limit Chiesi’s right to have audited Cornerstone’s records with respect to
any Calendar Quarter in connection with Chiesi’s year-end review. Such audit shall be conducted
exclusively for the purpose of verifying the accuracy of reports delivered by Cornerstone to Chiesi
pursuant to Section 6.4 and the accuracy of Cornerstone’s determination of the amounts payable or
paid by Cornerstone to Chiesi hereunder. The accountant shall sign a confidentiality agreement
prepared by Cornerstone and shall then have the right to examine the records kept pursuant to this
Section 6.5.1 and report to Chiesi the findings (but not the underlying data) of such examination
of records. The accountant shall provide a draft copy of the report to Chiesi and Cornerstone for
review and comment, and each of Chiesi and Cornerstone shall have thirty (30) days after receipt of
that report to review and comment on the report which comments shall be provided to the accountant
and to each other. The final report shall be provided simultaneously to Chiesi and Cornerstone by
the independent certified public accountant within twenty (20) days after the accountant’s receipt
and consideration of such comments. In the event that an audit has been initiated by Chiesi, the
records that have been the subject of the audit shall be kept until the later of (i) the expiry of
any time period set out in Section 6.5.2 for the payment or credit of any amounts owing or (ii) the
resolution of any dispute arising from the audit. If such examination of records reveals more than
a five percent (5%) underpayment of any amounts payable hereunder as compared to the amounts
actually reported by Cornerstone as payable to Chiesi, as determined by such examination for the
period which is the subject of such examination, the expenses for said accountant shall be borne by
Cornerstone.

          6.5.2 Adjustments. Cornerstone shall pay to Chiesi within forty-five (45) days after
the delivery of the accountant’s report pursuant to Section 6.5.1 any amounts determined by the
accountant to be payable by Cornerstone to Chiesi. If the accountant determines that Cornerstone
has overpaid Chiesi, Chiesi shall credit Cornerstone in an amount equal to such overpayment on the
immediately succeeding invoice rendered to Cornerstone; provided, however, that if this Agreement
has terminated or expired, then Chiesi shall pay to Cornerstone within forty-five (45) days after
the delivery of the accountant’s report pursuant to Section 6.5.1 an amount equal to such
overpayment.

     6.6 Withholding Taxes. (a) Chiesi and Cornerstone agree that all payments due to Chiesi from
Cornerstone hereunder shall be made by Cornerstone free and clear of, and without deduction for,
any Income or Withholding Taxes, except as otherwise provided in Section 6.3 and this Section 6.6.
If the fiscal or taxing authorities of any relevant jurisdiction assert that Income or Withholding
Taxes are required to be withheld from any payments due to Chiesi or its Affiliates from
Cornerstone or its Affiliates, or the tax laws (including statutes, regulations, treaties and
judicial or official interpretations of any of the foregoing) in one or more jurisdictions have
changed so as to require such treatment, then (i) the Party made aware of such assertion or change
in law shall inform the other Party within thirty (30) days and shall consult with the other Party
regarding the consequences of such assertion or change and (ii) until the conclusion of such
consultation Cornerstone and its Affiliates shall be entitled to deduct and withhold the applicable
Income or Withholding Tax from any applicable payments due to Chiesi

17

 

or its Affiliates and pay such Income or Withholding Tax over to the applicable fiscal or
taxing authority. If, after consultation with Chiesi, Cornerstone believes that it or any of its
Affiliates is required to withhold Income or Withholding Tax from any payment to or for the account
of Chiesi or its Affiliates, such amount shall be deducted from the amounts payable to or for the
account of Chiesi or its Affiliates and shall be paid by Cornerstone to the appropriate fiscal or
tax authorities, provided that Cornerstone shall however take all reasonable steps in order to
allow Chiesi to take advantage of the relevant double taxation treaty(ies) for the purpose of
minimizing withholding taxes on such amounts, so long as Chiesi and its Affiliates promptly
provides any forms, certificates or other documentation or information that Chiesi or its
Affiliates are required or reasonably requested by Cornerstone to provide in connection with such
minimization. Cornerstone shall promptly furnish Chiesi with copies of official tax receipts or
other appropriate evidence to support a claim for tax or other credit in respect of any sum so
withheld, and shall provide such assistance as Chiesi may reasonably require in obtaining any
refund of such amounts to which Chiesi or its Affiliates may be entitled, to the extent that such
assistance does not cause Cornerstone or its Affiliates to incur any liability in respect of any of
the taxes asserted to be due or other cost or expense. For purposes of this Agreement, “Income or
Withholding Tax” means (i) any tax, levy or charge imposed by a governmental authority that is
computed or determined by reference to gross or net receipts, revenues, sales, income, earnings,
profits or gains of Chiesi or any of its Affiliates or any office, branch, permanent establishment
or trade or business of Chiesi or any of its Affiliates, (ii) any tax, levy or charge imposed by a
governmental authority as a result of the payment or accrual of amounts to or for the account of
Chiesi or any of its Affiliates in respect of the grant of rights or sale of Product by Chiesi or
any of its Affiliates to Cornerstone or any of its Affiliates pursuant to this Agreement, and (iii)
any additional amount, penalty, interest or addition to tax imposed with respect to the foregoing
or cost or expense relating to the imposition or contest of the foregoing.

     6.7 Third Party Pricing. Nothing contained herein, however, shall be deemed to limit in any
way Cornerstone’s right to determine the prices at which the Products purchased by Cornerstone may
be sold by Cornerstone to any Third Party.

ARTICLE 7

MARKETING OF THE PRODUCT

     7.1 Marketing Plan. No later than [***], before the Transfer Date, Cornerstone shall provide
Chiesi with its proposed marketing plan for the Product during the first year of this Agreement,
and thereafter shall provide Chiesi with its proposed marketing plan no later than [***] months
before the second and subsequent years, as the case may be. Such proposed marketing plans shall be
duly carried out by Cornerstone, taking into account all comments and suggestions of Chiesi.
Furthermore, within [***] of the end of each Calendar Quarter, Cornerstone shall send Chiesi a
written report detailing advertising and promotional activities carried out in the said quarter.

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.

18

 

     7.2 Chiesi Approval of Marketing Materials. Cornerstone shall submit to Chiesi for Chiesi’s
prior written approval, copies of all marketing and promotional materials and copies of all other
printed materials which Cornerstone proposes at any time to use in relation to the promotion,
marketing, sale or offer for sale of the Product. If Chiesi fails to respond to a request to
approve any promotional or marketing material within [***] after receipt of Cornerstone’s
submission by Chiesi, such failure shall constitute approval of the submission.

     7.3 Compliance with Marketing Authorization. All promotional and sales material, including
advertisement, sales and training aids, if locally prepared and used by Cornerstone with respect to
the Product, shall fully comply with Applicable Laws and with the Marketing Authorization in the
Territory. In addition, Cornerstone will seek final approval from Chiesi in writing (such approval
not to be unreasonably withheld) before printing or distributing such promotional and sales
material. If Chiesi fails to comment on such material within [***] upon receipt thereof, then such
material shall be considered approved by Chiesi. Furthermore, all promotional and sales material
contemplated by this Section, along with all inner and outer packaging items of the Product, shall
clearly indicate the legend “Under license of CHIESI”.

     7.4 Prevailing Market Conditions. Cornerstone agrees to keep Chiesi reasonably and promptly
informed of all relevant market conditions prevailing within the Territory, which includes
providing Chiesi with information regarding development of prices, competing products and relevant
legal regulations.

     7.5 Chiesi Website. Chiesi shall grant Cornerstone the right to link to the healthcare
provider section of the Curosurf website from the Cornerstone website and, to the extent
applicable, shall grant Cornerstone website access rights commensurate with those granted to
physicians generally.

     7.6 Commercial Incentives and Minimum Commitments. Set forth on Appendix C hereto are
the agreed upon commercial incentives and minimum commitments relating to Cornerstone’s performance
under this Agreement.

ARTICLE 8

INTELLECTUAL PROPERTY

     8.1 Ownership of Intellectual Property. Chiesi or its Affiliates or licensors shall remain
the owner of the intellectual property relating to the Products including any and all rights to any
scientific, pharmaceutical or technical information, data, discovery, invention (whether patentable
or not), Know-How, substances, techniques, processes, systems, formulations, designs and expertise
relating to the Product which is not generally known to the public and any and all rights under any
and all patent applications and/or patents, now existing, currently pending or

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.

19

 

hereafter filed or acquired or licensed by Chiesi or any Affiliate of Chiesi relating to the
Product, and any foreign counterparts thereof and all divisionals, continuations,
continuations-in-part, any foreign counterparts thereof and all patents issuing on any of the
foregoing, and any foreign counterparts thereof, together with all registrations, reissues,
re-examinations, supplemental protection certificates, or extensions thereof, and any foreign
counterparts thereof (collectively, the “Chiesi Intellectual Property”).

     8.2 Improvements. Cornerstone shall promptly notify Chiesi of any Improvements. Any
Improvements, whether patentable or not, shall be the sole property of Chiesi, regardless of
inventorship. Cornerstone shall assign, and shall ensure that any of its employees, agents and
officers who are inventors of Improvements assign, to Chiesi, and hereby does assign, all rights to
such Improvements at no cost to Chiesi. Cornerstone shall provide Chiesi with reasonable support
in the filing and prosecution of any patent applications for Improvements and shall provide all
information and/or data in Cornerstone’s possession that is necessary to support any such patent
application.

     8.3 Enforcement. Cornerstone shall promptly inform Chiesi in writing of any actual or alleged
unauthorized use of the Chiesi Intellectual Property by a Third Party of which it becomes aware and
provide Chiesi with any available evidence of such unauthorized use. Chiesi shall have the right,
but not the obligation, to enforce for Chiesi’s own benefit (including by agreement or by
litigation) Chiesi’s rights in the Chiesi Intellectual Property at its own instigation.
Cornerstone shall reasonably cooperate with Chiesi to enforce such rights.

     8.4 Trademarks.

          8.4.1 Cornerstone shall only market and sell the Product in the Territory under the Trademark.
Subject to the terms of this Agreement, Chiesi grants to Cornerstone an exclusive license to use
the Trademark in connection with the import, use, sale, offer for sale, marketing and distribution
of the Product in the Territory in the Field of Use.

          8.4.2 Cornerstone acknowledges that Chiesi or its Affiliate or licensors are the owner of all
rights, title and interest to the Trademark and all associated goodwill and further acknowledges
that Chiesi may terminate this Agreement in accordance with the provisions of Section 12.4, if
Cornerstone takes any action which materially impairs any such right, title or interest or
challenges the validity, scope or enforceability of the Trademark, or the substantial and secret
nature of the Know-How in the Territory. For the avoidance of doubt, Chiesi shall not have any
rights with respect to Cornerstone’s logo and any other Cornerstone-owned trade dress the Parties
agree to include on the packages, labeling and inserts related to the Product.

          8.4.3 Cornerstone will not attack, dispute, or contest the validity or the ownership of the
Trademark or any registrations issued or issuing with respect thereto, both during the Term of this
Agreement and thereafter. Cornerstone’s use of the Trademark shall inure to the benefit of Chiesi,
for all purposes including trademark registrations. In the event Cornerstone acquires any rights
relating to the Trademark for any reason, Cornerstone agrees to assign, and hereby does assign, at
no cost, all such rights, together with any related goodwill, to Chiesi. Cornerstone shall use its
best efforts not to do any act which would or might endanger, destroy or similarly affect the value
of the goodwill pertaining to the Trademark nor do any act

20

 

which might support a petition to cancel any registration relating to the Trademark or cause
the applicable registrar to require a disclaimer of exclusive rights in such Trademark nor assist
any other person or other entity directly or indirectly in such act. Cornerstone will immediately
execute any documents presented to it by Chiesi to confirm Chiesi’s ownership of all such rights.

          8.4.4 Cornerstone shall ensure that each reference to and use of the Trademark by Cornerstone
is in a manner approved by Chiesi and accompanied by the acknowledgement as follows: “Curosurf is a
registered trademark of Chiesi Farmaceutici S.p.A.”

          8.4.5 Cornerstone shall comply with all reasonable instructions issued by Chiesi relating to
the form and manner in which the Trademark shall be used in connection with the marketing of the
Product by Cornerstone and to discontinue, upon notice from Chiesi, any practice relating to the
use of the Trademark which in Chiesi’s reasonable opinion would adversely affect the rights or
interest of Chiesi in such Trademarks. Cornerstone shall not alter the packaging of the Products
or conceal, obscure, remove or otherwise interfere with the Trademark or other markings including
an indication of the source of origin which may be placed on the Product for Chiesi. Cornerstone
shall ensure that the Product is promoted, distributed, handled, marketed, stored on its (or its
designee’s) premises, and shipped to its customers, in such a manner that would not depreciate the
goodwill associated with the Trademark used in association with the Product.

          8.4.6 Chiesi will be entitled to conduct all enforcement proceedings relating to the Trademark
and shall at its sole discretion decide what action, if any, to take in respect of any infringement
or alleged infringement of the Trademark or passing-off or any other claim or counter-claim brought
or threatened in respect of the use or registration of the Trademark. Any such proceedings shall
be conducted at Chiesi’s expense and for its own benefit. At Chiesi’s written request to
Cornerstone and Chiesi’s expense, Cornerstone shall reasonably cooperate with Chiesi in such
efforts. Chiesi shall at its own discretion decide any settlement for any such proceedings or
claims. Cornerstone shall be notified of such proceedings involving the Trademark regardless of
request for cooperation in such efforts within twenty (20) business days.

          8.4.7 If Chiesi elects not to exercise its right pursuant to Section 8.4.6, Chiesi shall
promptly notify Cornerstone in writing of its election, and of the circumstance of such
infringement. In such event Cornerstone shall have the right, but not the obligation, to take any
and all action, at its own cost and expense, to obtain a discontinuance of the alleged infringement
and/or to bring suit against such infringer.

          8.4.8 No settlement or consent judgment or other voluntary final disposition of a suit under
this Article 8 may be entered into by either Party without the prior written consent of the other
Party, such consent not to be unreasonably withheld. Chiesi shall execute or cause the execution of
such legal papers in connection with the foregoing as may be reasonably requested by Cornerstone.

          8.4.9 In the event of any claim, threat or suit by a Third Party against either Cornerstone or
Chiesi alleging infringement by the Product of any patents or other Intellectual Property Rights of
such Third Party, the Party receiving such notice shall promptly notify the other Party in writing
of such fact, and the Parties shall defend in close cooperation with each

21

 

other against such claim, threat or suit. Such defense shall be at Chiesi’s cost and expense
unless the alleged infringement relates to Cornerstone’s corporate logo or any other
Cornerstone-owned trade dress the Parties agree to include on the packages, labeling and inserts
related to the Product.

          8.4.10 In the event that a conflict arises between the interests of Chiesi and Cornerstone in
any litigation described in this Article 8, the Party that is not funding the litigation shall have
the right to be represented by counsel of its own choice and at its sole expense.

          8.4.11 Cornerstone shall not sell, market, distribute or use for any purpose any Product or
marketing, packaging or labeling materials related to the Product which are damaged, defective or
otherwise fail to meet the specification or quality standards or the trademark usage requirements
of this Agreement. Furthermore, during the Term, and after its termination for any reason
whatsoever, Cornerstone shall not use any trademark or trade name identical with or confusingly
similar to the Trademark and shall not apply, before any authority of any country, for the
registration of any internet domain name (nor any other creative expression that may be the subject
of registration), containing, in any form or graphic character, the name “Chiesi” and/or the
Trademark used hereunder (and/or any other denomination confusingly similar to the aforesaid
names).

     8.5 No Other Rights. Other than the right to purchase Product from Chiesi as permitted by
this Agreement and the limited license to the Trademark, Cornerstone shall not acquire any rights
to or under any Chiesi Intellectual Property. Except as set forth herein and therein, Cornerstone
shall have no right to use the trade names, trademarks or other intellectual property of Chiesi
except as provided in writing in advance by Chiesi. Upon termination of this Agreement,
Cornerstone will discontinue all use of the Chiesi name, Trademark and the Chiesi Intellectual
Property and discontinue all representation that it is or was an authorized representative of
Chiesi. This Section 8.5 shall survive the expiration or termination of this Agreement.

ARTICLE 9

REPRESENTATIONS, WARRANTIES AND COVENANTS

     9.1 Mutual Representations, Warranties and Covenants. Each Party represents, warrants and
covenants that:

          9.1.1 it is a corporation duly organized, validly existing and in good standing under the laws
of its jurisdiction of incorporation and has the corporate power and authority to execute, deliver,
and perform this Agreement;

          9.1.2 the execution of this Agreement and the performance thereof have been duly authorized by
all necessary corporate action on its part and do not conflict with the terms or conditions of any
agreement to which such Party is subject;

          9.1.3 when executed and delivered by it, this Agreement will constitute a legal, valid and
binding obligation of it, enforceable against it in accordance with the provisions of this
Agreement; and

22

 

          9.1.4 it shall perform its obligations under this Agreement in compliance with all Applicable
Laws.

     9.2 Additional Representations, Warranties and Covenants of Cornerstone.

          9.2.1 Cornerstone represents, warrants and covenants that: (a) it has duly investigated the
Know-How in order to determine its interest in entering into this Agreement; (b) it shall represent
the Product accurately and fairly and shall refrain from misleading or unethical business
practices; (c) it shall conduct its business in a manner that reflects favorably on the Product and
the good name, goodwill and reputation of Chiesi; (d) it shall avoid deceptive or unethical
practices, including disparagement of the Product and (e) it shall not make any representations,
warranties or guarantees to customers or other Third Parties or to the trade with respect to the
Specifications, features or capabilities of the Product that are inconsistent with the literature
or documentation provided by Chiesi.

          9.2.2 To its knowledge, Cornerstone (i) is not debarred, (ii) is not in the process of being
debarred, (iii) has not been threatened with debarment and (iii) does not use the services of any
persons who have been, or are in the process of being, debarred under 21 U.S.C. § 335a(a) of the
Act or any comparable law. Furthermore, neither Cornerstone nor, to its knowledge, any of its
officers, employees, or consultants has been convicted of an offense under (i) either a federal or
state law that is cited in 21 U.S.C. § 335(a) as a ground for debarment, denial of approval, or
suspension, or (ii) any other law cited in any comparable Applicable Law as a ground for debarment,
denial of approval or suspension.

          9.2.3 Cornerstone has all Agency consents necessary or desirable in performance of its
obligations hereunder and the commercial sale of the Product in the Territory.

          9.2.4 Cornerstone will not market the Product outside the Field of Use or outside the
Territory nor will it sell the Product to any Third Party for sale or distribution outside the
Field of Use or outside the Territory.

          9.2.5 All Product commercialized by Cornerstone, or under its authority, shall (i) be
imported, stored, handled, promoted, distributed, marketed, offered for sale and sold in compliance
with the terms of this Agreement, the Act and all Applicable Laws; (ii) be in accordance with and
conform to any applicable standards specified by the United States Pharmacopeia and Pharmacopeia
Forum and the European Pharmacopeia and Pharmacopeial Forum and (iii) from and after the time
delivered by Chiesi hereunder, be free from any material that would cause the Product to be
adulterated or misbranded within the meaning of the Act.

     9.3 Additional Representations, Warranties and Covenants of Chiesi.

          9.3.1 Chiesi represents, warrants and covenants, or shall require that its contract
manufacturers represent, warrant and covenant, that the Products at the time of manufacture shall
be free and clear of any lien or encumbrance. Chiesi further represents, warrants and covenants
that, to its knowledge, the purchase, sale, use, disposition, and advertisement of any Product or
the Trademark by Cornerstone will not infringe on or violate any patent, design, copyright,
trademark, trade secret, or other right of any Third Party, provided that said activities are not

23

 

performed in contravention of this Agreement. Chiesi has the right to grant the rights to
Cornerstone contemplated in this Agreement in the Territory.

          9.3.2 To its knowledge, Chiesi has not used, in any capacity associated with or related to the
manufacture of the Products, the services of any persons who have been, or are in the process of
being, debarred under 21 U.S.C. § 335a(a) or (b) or any comparable Regulatory Act. Furthermore,
neither Chiesi nor, to its knowledge, any of its officers, employees, or consultants has been
convicted of an offense under (i) either a federal or state law that is cited in 21 U.S.C. § 335(a)
as a ground for debarment, denial of approval, or suspension, or (ii) any other law cited in any
comparable Applicable Law as a ground for debarment, denial of approval or suspension.

          9.3.3 Chiesi has, and its contract manufacturer(s) has, all Agency consents necessary or
desirable in performance of its obligations hereunder and the manufacture of the Product for
commercial sale in the Territory.

          9.3.4 Chiesi and its Affiliates will not market the Product in the Field of Use in the
Territory nor will they sell the Product to any Third Party for sale or distribution in the Field
of Use in the Territory.

          9.3.5 The manufacture, generation, processing, packaging, distribution, transport, treatment,
storage, disposal and other handling of any Product by Chiesi, its Affiliates or its contract
manufacturer(s) until delivery to a carrier or freight forwarder shall (i) be in accordance with
and conform to the Specifications, cGMPs and Chiesi quality policies and guidelines; (ii) be in
accordance with and conform to any applicable standards specified by the United States Pharmacopeia
and Pharmacopeia Forum and the European Pharmacopeia and Pharmacopeial Forum, (iii) otherwise
conform to any provisions of the Regulatory Requirements not reflected in cGMPs, and (iv) be free
from defects in materials and workmanship and shall not be adulterated or misbranded within the
meaning of the Act; provided, however, that the representations and warranties provided in this
Section 9.3.5 do not apply to any Product to the extent that, after shipment by Chiesi, occurrences
affecting or altering the Product after they are delivered to the carrier, or actions taken or
failed to be taken after the Product was shipped, result in the Product failing to conform to
Specifications.

     9.4 Disclaimer. EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT, ALL WARRANTIES, CONDITIONS,
AND REPRESENTATIONS, WHETHER EXPRESS OR IMPLIED, ARISING BY LAW, CUSTOM, PRIOR ORAL OR WRITTEN
STATEMENT BY THE PARTIES, OR OTHERWISE (INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT) ARE HEREBY OVERRIDDEN, EXCLUDED AND DISCLAIMED.

ARTICLE 10

INDEMNIFICATION

     10.1 Indemnification by Cornerstone. Cornerstone hereby agrees to defend Chiesi and its
Affiliates and their respective directors, officers, employees, agents, successors and assigns from
and against any and all Claims of a Third Party and to indemnify and hold Chiesi

24

 

and its Affiliates and their respective directors, officers, employees, agents, successors and
assigns, harmless from and against any and all Losses to the extent arising from any such Claims of
a Third Party for (i) death or personal injury to the extent arising from the importation, storage,
handling, promotion, distribution, marketing, sale, use or consumption of the Product, (ii)
Cornerstone’s breach of its representations, warranties or covenants under this Agreement, the
Technical Agreement or Pharmacovigilance Agreement, or (iii) the negligence or willful misconduct
or wrongdoing of Cornerstone or any person for whose actions or omissions Cornerstone is legally
liable, except, in each case, to the extent that such Losses arise as a result of an item for which
Chiesi is obligated to indemnify Cornerstone pursuant to Section 10.1.

     10.2 Indemnification by Chiesi. Chiesi hereby agrees to defend Cornerstone and its Affiliates
and their respective directors, officers, employees, agents, successors and assigns from and
against any and all Claims of a Third Party and to indemnify and hold Cornerstone and its
Affiliates and their respective directors, officers, employees, agents, successors and assigns,
harmless from and against any and all Losses to the extent arising from any such Claims of a Third
Party for (i) Chiesi’s breach of its representations, warranties or covenants under this Agreement,
the Technical Agreement or Pharmacovigilance Agreement, or (ii) the negligence or willful
misconduct or wrongdoing of Chiesi, its contract manufacturer(s) of the Product, or any person for
whose actions or omissions Chiesi is legally liable, except, in each case, to the extent that such
Losses arises as a result of an item for which Cornerstone is obligated to indemnify Chiesi
pursuant to Section 10.1.

     10.3 Indemnification Procedures. No indemnity may be claimed by or given to the Party seeking
to rely on such indemnity:

          10.3.1 unless the Party claiming indemnity shall have promptly notified the other Party of the
relevant potential Loss upon becoming aware of such potential Loss except to the extent the failure
to provide such notice does not materially prejudice the Party providing such indemnity’s ability
to defend or contest any suit or claim relating to such potential Loss;

          10.3.2 where the Party seeking indemnification has made any admission or offer or any
settlement without the prior written consent of the indemnifying Party, which consent shall not be
unreasonably withheld or delayed; and

          10.3.3 unless the Party seeking indemnification has allowed the indemnifying Party to assume
full control of all proceedings in relation to any such potential Loss within thirty (30) days of
having been given notice of such proceedings; provided, that (i) the Party seeking indemnification
shall have the right to appoint independent counsel at its own cost to participate therein and (ii)
no compromise or settlement may be effected by the indemnifying Party without the prior written
consent of the other Party.

25

 

     10.4 Insurance. During the Term and for a period of [***] months thereafter, the Parties
shall obtain and/or maintain product liability insurance in such amounts as are reasonable given
(i) their responsibilities and liabilities under this Agreement and (ii) such amounts as may be
reasonable and customary within the industry in respect of the Product and country the subject of
this Agreement. On request, either Party shall provide the other Party with a certificate of such
insurance policy.

     10.5 Limitation on Liability. NOTWITHSTANDING THE FOREGOING WARRANTIES AND REPRESENTATIONS
AND THE FURTHER OBLIGATIONS OF THE PARTIES UNDER THIS AGREEMENT, EXCEPT FOR EACH PARTY’S
INDEMNIFICATION OBLIGATIONS PURSUANT TO THIS ARTICLE 10, AND SUBJECT TO ANY EXPRESS PROVISION TO
THE CONTRARY, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL,
STATUTORY, TREBLE, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING ANY CLAIM FOR DAMAGES BASED UPON
LOST PROFITS OR LOST BUSINESS OPPORTUNITY EXCEPT WHERE SUCH DAMAGES ARE THE RESULT OF EITHER
PARTY’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT.

ARTICLE 11

CONFIDENTIALITY

     11.1 Confidential Information. Each Party acknowledges that the other Party may disclose
certain information, data or know-how which the disclosing Party treats confidentially and
identifies as confidential or which the recipient knows or should have reason to believe is so
treated by the disclosing Party (the “Confidential Information”). If either Party
discloses such Confidential Information to the other, the receiving Party will (a) use at least the
same degree of care to maintain the secrecy of such Confidential Information as the receiving Party
uses to maintain the secrecy of its own confidential information, but in no event less than a
reasonable degree of care and (b) use the Confidential Information only to accomplish the purposes
of this Agreement.

     11.2 Disclosure. The receiving Party will not disclose the Confidential Information of the
disclosing Party to any person except those of the receiving Party’s employees or agents that
require access thereto to accomplish the purposes of this Agreement and have been made aware of the
confidentiality obligations herein, and, in the case of Chiesi, Dey for the purposes of the Dey
Settlement Agreement. If the receiving Party learns of an actual or potential unauthorized use or
disclosure of the disclosing Party’s Confidential Information, the receiving Party will promptly
notify the disclosing Party and, at the disclosing Party’s request, provide the disclosing Party
with reasonable assistance to recover its Confidential Information and to prevent subsequent
unauthorized uses or disclosures of such Confidential Information. Each Party

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.

26

 

acknowledges that (a) the unauthorized use or disclosure of any Confidential Information of the
disclosing Party will cause irreparable damage for which it will not have an adequate remedy at law
and (b) the disclosing Party will be entitled to injunctive and other equitable relief in such
cases.

     11.3 Limitations. Neither Party will have any confidentiality obligation with respect to the
Confidential Information of the disclosing Party that (a) the receiving Party independently knew or
develops without using such Confidential Information of the disclosing Party, (b) the receiving
Party lawfully obtains from another person under no obligation of confidentiality or (c) is or
becomes publicly available other than as a result of an act or omission of the receiving Party or
any of its employees or agents.

     11.4 Terms of Agreement. Except as set forth below, no announcement or other disclosure,
public or otherwise, concerning the financial or other terms of this Agreement shall be made,
either directly or indirectly, by either Party to this Agreement, except as may be legally
required, without first obtaining the written approval of the other Party as to the nature and text
of such announcement or disclosure, such approval and agreement not to be unreasonably withheld.
Notwithstanding the above, the Parties shall be free to publicly disclose information contained in
such press release that has been previously approved for disclosure by the other Party, without
further approvals from the other Party hereunder, to the extent there have been no material
additions or changes thereto.

     11.5 Publication of Data. Any publication of clinical and scientific data relevant to the
Product, generated under the terms of this Agreement, will be jointly planned and agreed upon in
advance.

     11.6 Confidentiality Term. All confidentiality provisions set out herein shall remain in full
force and effect during the Term and for a period of [***] years from the date of termination
hereof.

ARTICLE 12

TERM AND TERMINATION

     12.1 Term. This Agreement shall become effective on the Effective Date and shall remain in
force for ten (10) years starting from the Transfer Date (“Term”). Thereafter, this
Agreement shall automatically renew for successive one year periods, unless earlier terminated by a
Party upon six (6) months prior written notice.

     12.2 Termination upon Adverse Agency Action. Notwithstanding anything contained in this
Agreement, Cornerstone may terminate this Agreement upon thirty (30) Business Days prior written
notice in the event that any Agency takes any action, or raises any objection, that permanently
prevents Cornerstone from importing, marketing or selling the Product in the Territory.
Cornerstone shall not thereafter be obliged to purchase any Product other than that contained in
binding forecasts pursuant to Section 5.3.1 that have been submitted on or before the date of
Cornerstone’s notice.

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.

27

 

     12.3 Termination upon Regulatory Authority Action. In the event that a Regulatory Authority
requires Cornerstone to cease selling or distributing the Product in the Territory, Cornerstone
will have the right to terminate the Agreement upon thirty (30) Business Days’ prior written
notice. Cornerstone shall not thereafter be obliged to purchase any Product other than that
contained in binding forecasts pursuant to Section 5.3.1 that have been submitted on or before the
date of Cornerstone’s notice.

     12.4 Termination upon Default or Breach. In the event that either Party materially breaches
this Agreement, the breaching party shall have the opportunity to cure such breach within (i)
thirty (30) Business Days or (ii) a reasonably longer period if such breach is not capable of cure
within thirty (30) Business Days, in each case after receipt of written notice of such breach. If
the breach is not cured by the breaching party within the applicable cure period, the non-breaching
party shall be entitled to bring action against the breaching party to recover damages (other than
indirect, inconsequential or punitive damages) arising from such breach. The non-breaching party
shall have the right to terminate this Agreement upon thirty (30) Business Days written notice
(following the expiration of all cure periods) if it can prove that the consequences of the
breaching party’s breach or default have a material adverse effect on the economic value of this
Agreement to such Party and that, absent termination, such material adverse effect will be
permanent in nature.

     12.5 Termination upon Cancellation of the Equity Transaction. In the event that the
transactions contemplated by the Stock Purchase Agreement do not close by the earlier of (i)
October 31, 2009 or (ii) any mutually agreed upon extension thereof, Chiesi shall have the right to
terminate this Agreement upon [***] months written notice to Cornerstone. Cornerstone agrees that,
upon termination of this Agreement pursuant to this Section 12.5, Chiesi has the right to offer
employment to the Employees and that Cornerstone will not interfere with Chiesi’s attempts to hire
the Employees nor will it attempt to retain the Employees for employment in other areas of
Cornerstone’s business.

     12.6 Effects of Expiration or Termination. Upon expiry or termination of this Agreement, for
any reason whatsoever:

          12.6.1 Cornerstone shall promptly cease selling the Product (except Product currently in
stock, subject to Section 12.6.5) and using the Know-How and the Trademark;

          12.6.2 Cornerstone shall promptly relinquish and return free of charge to Chiesi all
pharmacological, toxicological and clinical original data in its possession and all technical
information, and Know-How or material relating to the Product; provided, however, that Chiesi shall
reimburse Cornerstone for reasonable out-of-pocket costs in connection with such return in the
event of termination of this Agreement by Cornerstone pursuant to Sections 12.2, 12.3 or 12.4;

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.

28

 

          12.6.3 Cornerstone shall promptly transfer free of charge to Chiesi, or to a company
designated by Chiesi, any and all IND(s), Marketing Authorization Application(s) and Marketing
Authorization held by Cornerstone; provided, however, that Chiesi shall reimburse Cornerstone for
reasonable out-of-pocket costs in connection with such transfer in the event of termination of this
Agreement by Cornerstone pursuant to Sections 12.2, 12.3 or 12.4;

          12.6.4 the liabilities of the Parties hereunder in respect of matters outstanding at the time
of such termination shall not be in any way affected;

          12.6.5 Chiesi shall have the option to repurchase all stocks of the Product, held by
Cornerstone within thirty (30) days of termination, in good and marketable condition at Supply
Price to Cornerstone. If the said option to repurchase the above stock of the Product is not
exercised by Chiesi, Cornerstone shall be entitled to continue to sell the above stock of the
Product in the Territory during the period of [***] months after termination but not thereafter;
and

          12.6.6 Sections 8.4.3, 8.4.11 and 12.4 and Articles 10, 11 and 13 shall survive termination of
this Agreement.

     12.7 Accrued Rights. Any termination of this Agreement shall be without prejudice to the
rights and remedies of either Party with respect to any of the provisions of this Agreement or
arising out of breaches prior to such termination and shall not relieve either of the Parties of
any obligations or liability accrued hereunder prior to such termination including indemnity
obligations and confidentiality obligations, nor rescind or give rise to any right to rescind
anything done or payments made or other consideration given hereunder prior to the time of such
termination and shall not affect in any manner any vested rights of either Party arising out of
this Agreement prior to such termination or expiration.

ARTICLE 13

GENERAL PROVISIONS

     13.1 No Restriction On Activities. Except as otherwise provided in this Agreement, nothing
provided herein shall in any way limit the Parties from entering into any other business venture or
restrict Chiesi from entering into similar marketing or sales agreements with other persons or
entities for the sale and distribution of other products or services.

     13.2 Legal Relationship. It is understood and agreed by the Parties that Cornerstone is an
independent contractor and is not the agent of Chiesi for any purpose whatsoever, and Cornerstone
has no right or authority in any way to obligate, assume or create any liability on the part of
Chiesi or to make any representations or warranties, whether express or implied, on behalf of
Chiesi, except as permitted by this Agreement.

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.

29

 

     13.3 Authority. Neither Chiesi nor Cornerstone shall have, or represent that it has, any
authority to enter into or make contracts in the name of, or on behalf of the other, to pledge the
other’s credit, to extend credit to the other or to bind the other in any way.

     13.4 Additions Or Alterations To Chiesi’s Products. Cornerstone shall not make any additions,
modifications or alterations to any Products without Chiesi’s prior written consent, which Chiesi
may withhold in its absolute discretion.

     13.5 Assignment; Binding Effect. Neither this Agreement nor any rights or obligations
hereunder may be assigned or otherwise transferred by either Party without the prior written
consent of the other, except that (i) Chiesi may assign this Agreement to any entity controlled by,
under common control with or controlling Chiesi and (ii) either party may assign this Agreement to
any successor to such party by means of sale of all or substantially all of the assets of such
party or sale of a majority of its voting stock. Subject to the foregoing, this Agreement is
binding upon, inures to the benefit of and is enforceable by the Parties to this Agreement and
their respective successors and assigns.

     13.6 No Third-Party Beneficiaries. The terms and provisions of this Agreement are intended
solely for the benefit of each Party hereto and their respective successors or permitted assigns,
and it is not the intention of the Parties to confer third-party beneficiary rights upon any other
person.

     13.7 Governing Law; Jurisdiction. Any and all rights, liabilities and any disputes relating
to this Agreement shall be construed under and governed by the laws of Italy. In the event of any
controversy or claim arising out of or relating to or in connection with any provision of this
Agreement or breach thereof, the Parties shall try to settle those conflicts amicably between
themselves. Should they fail to agree, the matter in dispute shall be finally and exclusively
referred to the courts in England having jurisdiction.

     13.8 Entire Agreement. This Agreement constitutes the entire Agreement between the Parties
hereto with respect to the subject matter and supersedes all previous agreements, whether written
or oral, with respect to such subject matter other than the Confidentiality Agreement between the
Parties dated January 6, 2009. No modification or alteration shall be binding unless in writing and
signed by both Parties.

     13.9 Notices. All notices and other communications sent to the applicable address or
facsimile number specified below shall be deemed to have been delivered at the earlier of (i) the
time of actual receipt by the addressee; (ii) if the notice is sent by facsimile transmission, the
time indicated on the transmitting party’s receipt of confirmation of transmission if that time is
during the addressee’s regular business hours on a Business Day, and otherwise at 9:00 a.m. on the
addressee’s next Business Day after such time; and (iii) if the notice is sent by a internationally
recognized, reputable express courier service, the time shown on the confirmation of delivery
provided by that service if that time is during the recipient’s regular business hours on a
Business Day, and otherwise at 9:00 a.m. on the recipient’s next Business Day after such time.

30

 

     Notices to Chiesi shall be addressed to:

Chiesi Farmaceutici S.p.A.

Via Palermo 26/A

43100 Parma

ITALY

Phone: +39.0521.2791

Fax: +39.0521.774468

Attention: President

Copy to: Head of Corporate Development and Legal and Corporate Affairs Director

     Notices to Cornerstone shall be addressed to:

Cornerstone Therapeutics Inc.

1255 Crescent Green Drive

Suite 250

Cary, North Carolina 27518

USA

Phone: 919-678-6611

Fax: 919-678-6599

Attention: President

Copy to: General Counsel

     Either Party may change its address by giving notice to the other Party.

     13.10 Counterparts. This Agreement (and any amendments hereto) may be executed in several
counterparts (including by facsimile) and all when so executed shall constitute one agreement,
binding on all of the Parties hereto, even though all of the Parties are not signatories to the
original or the same counterpart.

     13.11 Severability. If any provision of this Agreement, or the application of such provision
to any person or circumstance shall be held invalid or in violation of a mandatory provision of
Applicable Laws by a court or governmental agency of competent jurisdiction over this Agreement, it
shall be ineffective and deemed to have been deleted from this Agreement only to the extent of such
invalidity or violations and the remainder of this Agreement, or the application of such provision
to persons or circumstances other than those as to which it is held invalid, shall not be affected
thereby.

     13.12 Waiver. Subject to Applicable Laws and except as otherwise provided in this Agreement,
any Party to this Agreement may extend the time for performance of any obligation under this
Agreement of any other Party or waive compliance with any term or condition of this Agreement by
any other Party. No such extension or waiver shall be effective unless set forth in a written
instrument duly executed by the Party granting such extension or waiver. No delay in asserting or
exercising a right under this Agreement shall be deemed a waiver of that right.

31

 

     13.13 Further Assurances. At the request of any of the Parties, the other Party or Parties
shall (and shall use reasonable efforts to procure that any other necessary Third Parties shall)
execute and do all such documents, acts and things as may reasonably be required subsequent to the
signing of this Agreement for assuring to or vesting in the requesting Party the full benefit of
the terms hereof.

     13.14 Headings. The headings herein are for the convenience of the Parties only and shall not
be used in the interpretation of the provisions hereof.

     13.15 Publicity. Except as required by Applicable Law or stock exchange rules, the Parties
agree to keep this Agreement confidential until and except as they mutually agree on publicity.
Subject to Applicable Law, all publicity regarding this Agreement shall be jointly planned and
coordinated by and between the Parties.

     13.16 Force Majeure. Failure of either Party to perform its obligations under this Agreement
(excepting the obligation to make payments) shall not subject such Party to any liability to the
other if such failure is caused or occasioned by any Force Majeure. The Party suffering an event of
Force Majeure shall immediately notify the other Party and the Parties shall cooperate in good
faith in order to minimize the damages for the Parties; provided, however, that the Party whose
performance has not been hindered by the Force Majeure shall have the right to terminate this
Agreement, upon 30 (thirty) calendar days’ prior notice to the other, if an event of Force Majeure
continues for more than [***] consecutive months. Termination pursuant to the application of this
Section 13.16 shall not constitute a breach of this Agreement on the part of either Party.

     13.17 Language. All written communication between the Parties or their Affiliates relating to
this Agreement and its implementation shall be in English language.

[Signature Page Follows]

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.

32

 

     IN WITNESS THEREOF, the Parties hereto have caused this Agreement to be duly executed in
duplicate by their authorized officers as of the Effective Date.

	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	CHIESI FARMACEUTICI S.p.A.	 	CORNERSTONE THERAPEUTICS INC.	 	 
	 
	 	 	 	 	 	 	 	 
	By: 

Name:

	 	/s/ Paolo Chiesi
 

Dr. Paolo Chiesi
	 	By:

Name:
	 	/s/ Craig A. Collard
 

Craig A. Collard
	 	 
	Title:

	 	Vice President
	 	Title:
	 	President and CEO	 	 

 

 

Appendix A

to the License and Distribution Agreement made as of this 6th day of May, 2009 between Chiesi
FARMACEUTICI S.p.A. and Cornerstone THERAPEUTICS Inc.

	 	 	 
	Trademark
	 	 
	 
	 	 
	CUROSURF®

	 	USPTO Registration Number 1905266

	 	 	 	 	 
	Chiesi FARMACEUTICI S.p.A.

	 	 Cornerstone THERAPEUTICS Inc.	 	 
	 
	 	 	 	 
	/s/ Paolo Chiesi
 

(Signature)

	 	/s/ Craig A. Collard
 

(Signature)
	 	 

 

 

Appendix B

to the License and Distribution Agreement made as of this 6th day of May, 2009 between
Chiesi FARMACEUTICI S.p.A. and Cornerstone THERAPEUTICS Inc.

Floor Price equal to:

1.5 ml = [***]

3.0 ml = [***]

MINIMUM ORDER

500 units or multiples thereof, unless otherwise mutually agreed by the Parties

	 	 	 	 	 
	Chiesi FARMACEUTICI S.p.A.

	 	Cornerstone THERAPEUTICS Inc.	 	 
	 
	 	 	 	 
	/s/ Paolo Chiesi
 

(Signature)

	 	/s/ Craig A. Collard
 

(Signature)
	 	 

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.

 

 

Appendix C

to the License and Distribution Agreement made as of this 6th day of May, 2009 between
Chiesi FARMACEUTICI S.p.A. and Cornerstone THERAPEUTICS Inc.

Commercial Incentives + Minimum Commitments

During each contract year, on actual unit volumes of Product in excess of total volumes of Product
above the previous year: Supply Price ([***]%) — [***]%

	 	 	 
	Minimum Commitments:

	 	At least [***] FTEs devoted to the Product per calendar year
	 
	 	 
	 

	 	At least [***] per calendar year spent marketing expenses for the Product

	 	 	 	 	 
	Chiesi FARMACEUTICI S.p.A.

	 	Cornerstone THERAPEUTICS Inc.	 	 
	 
	 	 	 	 
	/s/ Paolo Chiesi
 

(Signature)

	 	/s/ Craig A. Collard
 

(Signature)
	 	 

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commissions.Exhibit 10.1

Exhibit 10.1

AMENDMENT AND ADDENDUM TO

COLLABORATION AND SERVICES AGREEMENT

This Amendment and Addendum (the “Amendment”) to the Collaboration and Services Agreement dated November 28,
2005 (the “Agreement”) by and between Neurobiological Technologies, Inc., a Delaware corporation
(“NTI”) and Neutron Ltd., a Bermuda limited company (“Neutron”), is entered into as of June 23, 2009
(the “Amendment Effective Date”) by and among NTI, Neutron, and Celtic Pharma Development Services America
Inc., a Delaware corporation (“Celtic Services”). Capitalized terms used but not defined herein shall have the
meanings ascribed to them in the Agreement.

Recitals

Whereas, from and after November 28, 2005 to the Amendment Effective Date, NTI has provided to
Neutron certain services in connection with the research and development of the Product pursuant to the terms and
conditions of the Agreement;

Whereas, Celtic Pharma Development Services Bermuda Ltd., a Bermuda limited company (“Parent”), the
sole shareholder of Celtic Services, has entered into one or more agreements whereby Parent has agreed to assume the
obligations of developing and commercializing the Product on behalf of Neutron;

Whereas, Parent and Celtic Services have entered into one or more agreements whereby Parent has engaged Celtic
Services to perform development services occurring in the United States for Parent;

Whereas, Parent and Neutron desire that, from and after the Amendment Effective Date, the rights and
obligations of Neutron under the Agreement be assigned to, and assumed by, Celtic Services, as and to the extent set
forth herein, and NTI has agreed to consent to such assignment and assumption;

Whereas, Celtic Services desires to assume the services previously performed by NTI in connection with the
research and development of the Product; and

Whereas, NTI has agreed to consent to the foregoing assignment of development services from Neutron to Celtic
Services and to the assumption by Celtic Services of the services previously provided by NTI.

Now, Therefore, in consideration of the above premises and the covenants contained herein and for other good
and valuable consideration the receipt and sufficiency of which is hereby acknowledged, each of the parties to this
Amendment (collectively, the “Parties”) hereby agree as follows:

 

4

 

Amendment

1. Assignment and Assumption of Agreement. From and after the Amendment Effective Date, pursuant to Section
11.1(b)(i) of the Agreement and subject to the terms and conditions contained herein, (a) Neutron hereby conveys,
assigns, transfers and delivers all of its rights and obligations under the Agreement to Celtic Services, (b) Celtic
Services hereby receives and accepts such rights and assumes the duties and obligations of Neutron with respect
thereto, and (c) NTI hereby consents to such assignment and assumption.

2. Product Development Services. Notwithstanding anything to the contrary set forth in Article 2 of the
Agreement, from the Amendment Effective Date until the Expiration Date (defined below in Section 4), NTI shall perform
only those services relating to the Collaboration Work as mutually agreed between Vicky Hines on behalf of Celtic
Services and David Chou on behalf of NTI (the “Amended Services”). In connection with the foregoing, the
Steering Committee is hereby disbanded as of the Amendment Effective Date. The Parties hereby agree that from and
after the Amendment Effective Date, (a) none of the Parties shall have any rights or obligations under Sections 2.1,
2.2, 2.3, 2.4, 2.6, 2.7, 2.10 and 2.11 of the Agreement, and such Sections shall be terminated and shall be of no
further force or effect, (b) Section 2.5 shall terminate on the Expiration Date, and (c) Sections 2.8 and 2.9 of the
Agreement shall continue in effect, subject to the assignment and assumption of the Agreement described in Section 1 of
this Amendment. For purposes of clarification, Neutron and Celtic Services acknowledge and confirm their obligations
to make available on a timely basis all information reasonably requested by NTI which may include clinical trial data,
development plans and licensing terms for the Product.

3. Assignment and Assumption of Payment, Indemnity and Insurance Obligations. Notwithstanding anything to the
contrary set forth herein or in the Agreement, from and after the Amendment Effective Date, all rights and obligations
of Neutron pursuant to Sections 4.1 and 4.2 of the Agreement are hereby assigned to and assumed by Celtic Services and
Parent.

4. Term and Termination. Notwithstanding anything to the contrary set forth in the Agreement, the term of the
Agreement, as amended hereby, shall expire on June 30, 2009 (the “Expiration Date”) unless earlier terminated in
accordance with Section 9.4 or Section 9.5 of the Agreement. Upon such termination, the surviving obligations of the
Parties shall be as set forth in Section 9.7 of the Agreement.

5. No Other Amendment. Except as specifically amended by this Amendment, the terms and conditions of the
Agreement shall remain unchanged and shall continue in full force and effect.

6. Governing Law. This Amendment shall be construed and the respective rights and obligations of the Parties
determined according to the substantive laws of the State of New York, notwithstanding any contrary conflict of laws
provisions thereof.

7. Counterparts; Facsimile. This Amendment may be executed in one or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Signatures delivered by
facsimile shall be as effective as original signatures.

 

5

 

In Witness Whereof, this Amendment and Addendum to Collaboration and Services Agreement has been executed by the
undersigned, effective as of the date first written above.

	 	 	 	 	 
	NTI:	 	Neurobiological Technologies, Inc.
	 
	 	 	 	 
	 

	 	By:
	 	/s/ Matthew M. Loar
	 

	 	 	 	 
	 

	 	Name:
	 	Matthew M. Loar
	 

	 	 	 	 
	 

	 	Title:
	 	Chief Financial Officer
	 

	 	 	 	 
	 
	 	 	 	 
	Neutron:	 	Neutron Ltd.
	 
	 	 	 	 
	 

	 	By:
	 	/s/ L.M. Rhoads
	 

	 	 	 	 
	 

	 	Name:
	 	L.M. Rhoads
	 

	 	 	 	 
	 

	 	Title:
	 	Director
	 

	 	 	 	 
	 
	 	 	 	 
	Celtic Services:	 	Celtic Pharma Development Services America Inc.
	 
	 	 	 	 
	 

	 	By:
	 	/s/ Patrick O’Connor
	 

	 	 	 	 
	 

	 	Name:
	 	Patrick O’Connor
	 

	 	 	 	 
	 

	 	Title:
	 	CEO
	 

	 	 	 	 
	 
	 	 	 	 
	Consent and Acknowledgement:
	 	 	 	 
	 
	 	 	 	 
	 	 	Celtic Pharma Development Services Bermuda Ltd.
	 
	 	 	 	 
	 

	 	By:
	 	/s/ L.M. Rhoads
	 

	 	 	 	 
	 

	 	Name:
	 	L. M. Rhoads
	 

	 	 	 	 
	 

	 	Title:
	 	CAO
	 

	 	 	 	 

 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}]]